Literature DB >> 24829107

Telomerase as a "stemness" enzyme.

Feng Kong1, ChengYun Zheng, DaWei Xu.   

Abstract

Pluripotent or multipotent stem cells are involved in development and tissue homeostasis; they have the ability to self-renew and differentiate into various types of functional cells. To maintain these properties, stem cells must undergo sustained or unlimited proliferation that requires the stabilization of telomeres, which are essential for chromosome end protection. Telomerase, an RNA-dependent DNA polymerase, synthesizes telomeric DNA. Through the lengthening of telomeres the lifespans of cells are extended, or indefinite proliferation is conferred; this is intimately associated with stem cell phenotype. This review highlights our current understanding of telomerase as a "stemness" enzyme and discusses the underlying implications.

Mesh:

Substances:

Year:  2014        PMID: 24829107     DOI: 10.1007/s11427-014-4666-6

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  25 in total

Review 1.  The role of telomeres and telomerase reverse transcriptase isoforms in pluripotency induction and maintenance.

Authors:  Jonathan H Teichroeb; Joohwan Kim; Dean H Betts
Journal:  RNA Biol       Date:  2016-01-19       Impact factor: 4.652

2.  Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms.

Authors:  Jenny Dahlström; Xiaolu Zhang; Mehran Ghaderi; Malin Hultcrantz; Magnus Björkholm; Dawei Xu
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

3.  TERT Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker.

Authors:  Li Liu; Cheng Liu; Omid Fotouhi; Yidong Fan; Kun Wang; Chuanyou Xia; Benkang Shi; Guangyong Zhang; Kexin Wang; Feng Kong; Catharina Larsson; Sanyuan Hu; Dawei Xu
Journal:  Oncologist       Date:  2017-07-28

4.  TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.

Authors:  Kun Wang; Tiantian Liu; Cheng Liu; Yan Meng; Xiaotian Yuan; Li Liu; Nan Ge; Jikai Liu; Chang Wang; Hongbo Ren; Keqiang Yan; Sanyuan Hu; Zhonghua Xu; Yidong Fan; Dawei Xu
Journal:  Oncologist       Date:  2015-02-05

5.  The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression.

Authors:  Xiaolu Zhang; Bingnan Li; Nick de Jonge; Magnus Björkholm; Dawei Xu
Journal:  Oncotarget       Date:  2015-03-10

6.  TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.

Authors:  Kun Wang; Tiantian Liu; Nan Ge; Li Liu; Xiaotian Yuan; Jikai Liu; Feng Kong; Chang Wang; Hongbo Ren; Keqiang Yan; Sanyuan Hu; Zhonghua Xu; Magnus Björkholm; Yidong Fan; Shengtian Zhao; Cheng Liu; Dawei Xu
Journal:  Oncotarget       Date:  2014-12-15

7.  Trend of telomerase activity change during human iPSC self-renewal and differentiation revealed by a quartz crystal microbalance based assay.

Authors:  Yitian Zhou; Ping Zhou; Yinqiang Xin; Jie Wang; Zhiqiang Zhu; Ji Hu; Shicheng Wei; Hongwei Ma
Journal:  Sci Rep       Date:  2014-11-10       Impact factor: 4.379

Review 8.  Genetic Engineering of Mesenchymal Stem Cells to Induce Their Migration and Survival.

Authors:  Adam Nowakowski; Piotr Walczak; Barbara Lukomska; Miroslaw Janowski
Journal:  Stem Cells Int       Date:  2016-05-03       Impact factor: 5.443

Review 9.  Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications.

Authors:  Tiantian Liu; Xiaotian Yuan; Dawei Xu
Journal:  Genes (Basel)       Date:  2016-07-18       Impact factor: 4.096

10.  TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma.

Authors:  Hong Xie; Tiantian Liu; Na Wang; Viveca Björnhagen; Anders Höög; Catharina Larsson; Weng-Onn Lui; Dawei Xu
Journal:  Oncotarget       Date:  2014-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.